FDA approves Novartis combo therapy for aggressive type of thyroid cancer

09:13 EDT 4 May 2018 | Reuters

(Reuters) - The U.S. Food and Drug Administration on Friday approved Novartis AG's combination therapy to treat an aggressive type of thyroid cancer.

More From BioPortfolio on "FDA approves Novartis combo therapy for aggressive type of thyroid cancer"